2020 Guide to Patient Support Services


Exelixis Access Services (EASE) includes a set of personalized ­support programs that offer a full range of services designed to support healthcare providers and patients who are prescribed Exelixis oncology drugs Cabometyx (cabozantinib) or Cometriq (cabozantinib).

Cabometyx is a kinase inhibitor indicated for the treatment of patients with advanced renal-cell carcinoma, and for the treatment of patients with liver cancer (hepatocellular carcinoma) after treatment with sorafenib. Cometriq is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (Table).


The EASE program services provide financial, access, and reimbursement support for eligible patients who have been subscribed an Exelixis medication.

Cabometyx 5-Day Free Trial Program

Provides free drug to help patients start Cabometyx treatment quickly.

Cabometyx Quick Start Program

Provides free drug to eligible patients who experience a payer decision delay of 5 days or more.

EASE $0 Co-Pay Program

Eligible patients with commercial insurance will pay $0 per month for Cabometyx or for Cometriq, for a maximum benefit of $25,000 per year. Patients with government insurance are excluded. Additional eligibility restrictions apply.

Cabometyx Dose Exchange Program

Provides a free 15-tablet supply of Cabometyx in the lower dose to help patients who require a dose reduction.

EASE Patient Assistance Program

Eligible patients who are uninsured or are insured but cannot afford the cost of the medication may receive Cabometyx or Cometriq free of charge.


EASE Co-Pay Program

To be eligible for this program, patients must have commercial health insurance and be prescribed Cabometyx or Cometriq.

EASE Patient Assistance Program

The EASE Patient Assistance Program offers Cabometyx or Cometriq for patients who are uninsured or underinsured, and meet the Patient Assistance Program eligibility criteria.

Cabometyx Quick Start Program

New patients with a diagnosis for which Cabometyx is indicated who experience a payer delay of more than 5 days can receive a 15-day supply of Cabometyx.

Cabometyx Dose Exchange Program

The Dose Exchange Program is only available for Cabometyx dose reductions. Patients may receive a one-time, 15-day supply of 40 mg and 20 mg of the drug through the Dose Exchange Program.

Patients are required to return unused drugs.


The enrollment process for the EASE program is drug-specific. The application for the Cabometyx EASE program requires completion of the EASE Enrollment and Patient Authorization forms. These must be submitted by fax to 844-901-3273, along with a copy of the insurance card. More information about the EASE program for Cabometyx can be obtained by calling 844-900-3273.

Information about enrollment in the Cometriq EASE program can be obtained by calling 877-977-9118.


The EASE program provides additional services for Cabometyx and for Cometriq.

Access and Reimbursement Support provides dedicated support specialists to assist healthcare professionals with regard to benefit investigations, prior authorizations, appeals, and delivery coordination.


Patient support programs

Cabometyx (cabozantinib)
Advanced renal-cell carcinoma; treatment of hepatocellular carcinoma, after treatment with sorafenib
Patient support programs

Cometriq (cabozantinib)
Progressive, metastatic medullary thyroid cancer
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: